- Home
- AKBA vs MSC Comparison
AKBA vs MSC Comparison
Compare AKBA & MSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKBA
- MSC
- Stock Information
- Founded
- AKBA 2007
- MSC 2000
- Country
- AKBA United States
- MSC Hong Kong
- Employees
- AKBA N/A
- MSC N/A
- Industry
- AKBA Biotechnology: Pharmaceutical Preparations
- MSC Hotels/Resorts
- Sector
- AKBA Health Care
- MSC Consumer Discretionary
- Exchange
- AKBA Nasdaq
- MSC Nasdaq
- Market Cap
- AKBA 861.7M
- MSC 766.5M
- IPO Year
- AKBA 2014
- MSC 2018
- Fundamental
- Price
- AKBA $2.88
- MSC $4.31
- Analyst Decision
- AKBA Strong Buy
- MSC
- Analyst Count
- AKBA 5
- MSC 0
- Target Price
- AKBA $6.90
- MSC N/A
- AVG Volume (30 Days)
- AKBA 2.9M
- MSC 10.3K
- Earning Date
- AKBA 11-06-2025
- MSC 11-04-2025
- Dividend Yield
- AKBA N/A
- MSC N/A
- EPS Growth
- AKBA N/A
- MSC N/A
- EPS
- AKBA N/A
- MSC N/A
- Revenue
- AKBA $203,733,000.00
- MSC $679,264,000.00
- Revenue This Year
- AKBA $43.91
- MSC $8.92
- Revenue Next Year
- AKBA $32.09
- MSC N/A
- P/E Ratio
- AKBA N/A
- MSC N/A
- Revenue Growth
- AKBA 16.75
- MSC 15.03
- 52 Week Low
- AKBA $1.26
- MSC $2.30
- 52 Week High
- AKBA $4.08
- MSC $7.40
- Technical
- Relative Strength Index (RSI)
- AKBA 47.89
- MSC 54.21
- Support Level
- AKBA $2.83
- MSC $3.74
- Resistance Level
- AKBA $3.02
- MSC $4.00
- Average True Range (ATR)
- AKBA 0.12
- MSC 0.25
- MACD
- AKBA 0.03
- MSC 0.06
- Stochastic Oscillator
- AKBA 56.94
- MSC 50.42
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
About MSC Studio City International Holdings Limited
Studio City International Holdings Ltd is a gaming, retail, and entertainment resort located in Cotai, Macau. It operates Studio City Casino with around 250 mass-market gaming tables; including tables for VIP rolling chip operations, and 552 gaming machines. Studio City features luxury hotel rooms, diverse food and beverage establishments, and complementary retail space. In addition, the company offers non-gaming attractions, including the world's first figure-8 Ferris wheel, a deluxe nightclub and karaoke venue, a live performance arena, an outdoor and an indoor water park. Geographically, the company derives the majority of its revenue from the Macau region.